×
About 357 results

ALLMedicine™ Papillary Tumors Center

Research & Reviews  171 results

Adenomatoid Tumor: A Review of Pathology With Focus on Unusual Presentations and Sites,...
https://doi.org/10.1097/PAP.0000000000000278
Advances in Anatomic Pathology; Karpathiou G, Hiroshima K et. al.

Aug 2nd, 2020 - Adenomatoid tumors have been described almost a century ago, and their nature has been the subject of debate for decades. They are tumors of mesothelial origin usually involving the uterus, the Fallopian tubes, and the paratesticular region. Adeno...

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
https://www.ncbi.nlm.nih.gov/pubmed/32645193
Oncology (Williston Park, N.Y.); Wright KM

Jul 9th, 2020 - The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are i...

Endoscopic papillectomy of benign papillary tumors: A single-center experience.
https://doi.org/10.1097/MD.0000000000020414
Medicine Lü S, Jiang M et. al.

Jun 2nd, 2020 - Endoscopic treatment of duodenal papillary tumors is well described. This study aims to provide new evidence for the treatment of benign papillary tumors through comparisons between endoscopic snare papillectomy (ESP) and endoscopic mucosal resect...

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to...
https://clinicaltrials.gov/ct2/show/NCT03335059

Apr 14th, 2020 - This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free...

Ciliated Muconodular Papillary Tumor of the Lung: Thin-Section CT Findings of 16 Cases.
https://doi.org/10.2214/AJR.19.21945
AJR. American Journal of Roentgenology; Onishi Y, Kusumoto M et. al.

Jan 22nd, 2020 - OBJECTIVE. The purpose of this article was to assess thin-section CT features of ciliated muconodular papillary tumors (CMPTs) of the lung and correlations between radiologic and pathologic findings. MATERIALS AND METHODS. Thin-section CT findings...

see more →

Guidelines  1 results

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  181 results

Novel Indications and New Drugs for the Treatment of Bladder Cancer
https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/novel-indications-and-new-drugs-for-the-treatment-of-bladder-cancer/

Aug 24th, 2020 - Pembrolizumab: On January 8, 2020, pembrolizumab (Keytruda) was approved by the U.S. Food and Drug Administration (FDA) for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or w...

Adenomatoid Tumor: A Review of Pathology With Focus on Unusual Presentations and Sites,...
https://doi.org/10.1097/PAP.0000000000000278
Advances in Anatomic Pathology; Karpathiou G, Hiroshima K et. al.

Aug 2nd, 2020 - Adenomatoid tumors have been described almost a century ago, and their nature has been the subject of debate for decades. They are tumors of mesothelial origin usually involving the uterus, the Fallopian tubes, and the paratesticular region. Adeno...

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
https://www.ncbi.nlm.nih.gov/pubmed/32645193
Oncology (Williston Park, N.Y.); Wright KM

Jul 9th, 2020 - The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are i...

Endoscopic papillectomy of benign papillary tumors: A single-center experience.
https://doi.org/10.1097/MD.0000000000020414
Medicine Lü S, Jiang M et. al.

Jun 2nd, 2020 - Endoscopic treatment of duodenal papillary tumors is well described. This study aims to provide new evidence for the treatment of benign papillary tumors through comparisons between endoscopic snare papillectomy (ESP) and endoscopic mucosal resect...

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to...
https://clinicaltrials.gov/ct2/show/NCT03335059

Apr 14th, 2020 - This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free...

see more →

News  3 results

FDA approves pembrolizumab for BCG-unresponsive NMIBC with CIS
https://www.mdedge.com/hematology-oncology/article/215228/genitourinary-cancer/fda-approves-pembrolizumab-bcg-unresponsive?channel=39313
Laura Nikolaides

Jan 8th, 2020 - The Food and Drug Administration has approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or with.

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

Expanding the Scope of Cystoscopy: Imaging Agent Illuminates More Lesions
https://www.onclive.com/publications/oncology-live/2011/september-2011/expanding-the-scope-of-cystoscopy-imaging-agent-illuminates-more-lesions

Oct 10th, 2011 - Neal D. Shore, MD Although cystoscopy is a mainstay in diagnosing bladder cancer and monitoring its recurrence, researchers have been seeking to improve upon its ability to detect early evidence of cancer, particularly flat lesions and small papil...

see more →